Invest now
Novartis India share price
High risk
- ₹1,570.30(-2.06%)July 17, 2026 15:52:27 PM IST
- NSE
- BSE
- Vol : 27.77 K (NSE + BSE)Last 20 day avg : 49.86 K
Novartis India is trading -2.06% lower at Rs 1,570.30 as compared to its last closing price. Novartis India has been trading in the price range of 1,597.35 & 1,537.20. The company posted a net profit of 25.25 Crores in its last quarter.Listed peers of Novartis India include Sun Pharmaceutical Industries (-0.87%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (-4.72%).The Mutual Fund holding in Novartis India was at -% in . The MF holding has - from the last quarter. The FII holding in Novartis India was at 0.17% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 19 Jul 2026, 06:37 AM IST
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation-12.45The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Novartis India News
Novartis India Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,933.10 | -0.87 | 4,63,804.52 | 38.74 | 5.6 | - | - |
| Divi's Laboratories | 7,258.05 | -0.84 | 1,92,678.42 | 74.01 | 11.59 | - | - |
| Torrent Pharmaceuticals | 4,766.60 | -4.72 | 1,61,373.73 | 76.16 | 20.12 | - | - |
| Cipla | 1,418.40 | -0.77 | 1,14,584.78 | 27.78 | 3.35 | - | - |
| Zydus Lifesciences | 1,142.75 | -0.93 | 1,13,894.32 | 21.38 | 4.28 | - | - |
Mutual Fund Ownership
View allNovartis India Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-23 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-28 | Quarterly Results |
| 2025-10-28 | Quarterly Results |
| 2025-05-09 | Audited Results & Final Dividend |
About the company Novartis India
- IndustryBiotechnology & Drugs
- ISININE234A01025
- BSE Code500672
- NSE CodeNOVARTIND
Novartis India Limited is an India-based pure-play medicines company. The Company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are added for continued investment into R&D and manufacturing scale. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences. Its pipeline includes AAA614 Solid tumors, AAA617 Pluvicto Oligometastatic prostate cancer, Pluvicto Metastatic hormone sensitive prostate cancer (mHSPC), 225Ac-PSMA-617 Metastatic castration-resistant prostate cancer (mCRPC), and others.
Novartis India Share Price FAQs
Novartis India is trading at 1570.30 as on Fri Jul 17 2026 10:22:27. This is -2.06% lower as compared to its previous closing price of 1603.40.
The market capitalization of Novartis India is 3853.15 Cr as on Fri Jul 17 2026 10:22:27.
The 52 wk high for Novartis India is 1722.20 whereas the 52 wk low is 750.00
Novartis India can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 25.09
- Dividend Yield: 0.00%
- D/E ratio: 0.00
Novartis India reported a net profit of 93.18 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Novartis India QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.